Mark Frydenberg
Monash University, Cabrini Hospital, Monash Health, The Royal Melbourne Hospital, Australian Hearing
Papers
10
Total Citations
703
H-Index
8
About
Mark Frydenberg is a prominent urological surgeon and researcher whose work has fundamentally shaped our understanding of surgical approaches to urological cancers, particularly prostate, bladder, and kidney cancer. His research has consistently focused on comparing minimally invasive and robotic-assisted surgical techniques against traditional open surgery, generating evidence that directly informs clinical decision-making worldwide. His Cochrane systematic review on radical prostatectomy techniques (2017, 233 citations) and companion publications established critical benchmarks for evaluating laparoscopic and robotic approaches, while his meta-analysis on robotic versus open radical cystectomy (2018, 136 citations) brought similar rigor to bladder cancer surgery. Beyond surgical technique comparisons, Frydenberg has contributed meaningfully to understanding surgical quality markers, demonstrating through registry data how positive surgical margin rates have declined over a decade — a tangible indicator of improving surgical standards. His innovative work on 3D prostate cancer organoids for high-throughput drug screening (2021, 67 citations) reveals a forward-looking commitment to advancing preclinical cancer therapeutics. With research grounded in both Australasian clinical practice and international collaboration, Frydenberg has established himself as a leading voice in evidence-based urological oncology, bridging surgical excellence with translational science.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10